ImmuPharma PLC is stepping up efforts to secure a licensing deal for its P140 autoimmune platform, with discussions underway with multiple potential partners under confidentiality agreements.
Solvonis Therapeutics plc (LON: SVNS) Logo SVN-015 accepted into US NIDA funded programme
Solvonis’ Novel Compound SVN-015 Accepted into US NIDA-Funded Addiction Treatment Discovery Program for Methamphetamine and Cocaine Addiction
ImmuPharma PLC (LON: IMM) Launch of New Website & Corporate Update
www.immupharma.co.uk
Tim McCarthy, Chief Executive Officer of ImmuPharma PLC talks to Zak Mir
Zak Mir talks to Tim McCarthy, CEO of Immupharma, the speciality biopharmaceutical company that discovers and develops peptide-based therapeutics, announcing the filing of a groundbreaking new patent application for its
Transforming Biotech: Insights from Tim McCarthy, CEO of ImmuPharma
ImmuPharma PLC (AIM: IMM) CEO Tim McCarthy spoke with Zak Mir. In the world of biotechnology, companies often face unique challenges, particularly when it comes to navigating public markets and
Immupharma PLC (LON:IMM) proves unique Mechanism of Action-P140
ImmuPharma PLC (LSE:IMM), a leading specialist in peptide based drug discovery and development, announces a significant milestone in evidencing the unique mechanism of action (“MOA”) of its P140 autoimmune technology
Faron Pharmaceuticals Ltd (AIM:FARN) Results of Oversubscribed Placing
Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company focused on tackling cancers via novel immunotherapies, announces that the Bookbuild, announced on 5 February 2025, is now closed.
Immupharma PLC (LON:IMM) Breakthrough Findings into Autoimmune Diseases
ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, announces innovative groundbreaking advancements in its preclinical research program focused on P140 and the pathogenesis of autoimmune diseases.
Graft Polymer (UK) (LON:GPL) Business Update
Update on Recent Developments
ImmuPharma anticipates advancement in clinical trial stages.
ImmuPharma PLC (AIM:IMM, OTC:IMMPF) plans to focus this year on advancing Lupuzor, its lupus treatment, into phase II/III clinical trials later in the year.
Immupharma PLC (AIM:IMM) Finals results for y/e 31 December 2021
ImmuPharma PLC (LSE:IMM), (“ImmuPharma” or the “Company”), the specialist drug discovery and development company, is pleased to announce its final results for the twelve months ended 31 December 2021 (the
Immupharma PLC (AIM:IMM) UPDATE on P140 (LUPUZORT) clinical progress
Data confirms positive readout from P140 PK study